Fig. 7: Compound 89 inhibited tumor growth and metastasis in vivo.
A Representative images of the primary tumors removed from mice after administration of 89 (10 mg kg−1) or PBS once every 2 days for 28 day. B Primary tumor volume was measured each week (**p < 0.01). C Primary tumor weight in each group was measured (**p < 0.01). D Primary tumors were fixed and paraffin embedded. Five-micrometer (5 μm) sections were analyzed by IHC staining using anti-Ki-67 and anti-PCNA antibodies. Scale bar, 100 μm. E, F Metastatic lung nodules were visualized and then counted manually, and the differences were evaluated with Student t test (**p < 0.01). G Ex vivo bioluminescence images were obtained for selected mice in each group to check the effect of 89 against distant metastasis. H The metastasis incidence to distant organs was quantified. I Primary tumor sections were stained for α-tubulin (green) and β-tubulin (green), and nuclei were counterstained with DAPI (blue). Scale bar, 100 μm. J Primary tumors were lysed and applied to immunoblotting analysis using α-tubulin and β-tubulin antibodies, with actin as a loading control. K Primary tumors were lysed and applied to immunoblotting analysis using the indicated antibodies, with actin as a loading control. Bars represent mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 versus the control group.
